Subtype

Prostate Neoplasm

Non-malignant1,453 active trials24 approved drugs58 evidence items

NCIt: C3343
MeSH: D011471

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (260)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 126–150 of 260 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinicopathologic Spectrum and Intraprostatic Heterogeneity of Primary Mismatch Repair-Deficient Prostate Cancer.
Darrell Martin, Carol C Cheung, Chen Yang et al. · Am J Surg Pathol · Sep 15, 2026 · PMID 42740602 · candidate dictionary pubmed
Development and validation of a preoperative 18F-PSMA-1007 PET/MR prognostic model for predicting biochemical recurrence in prostate cancer: a multicentre study.
Jiajia Hu, Hangxing Chunyu, Yihong Yang et al. · Eur J Nucl Med Mol Imaging · Sep 15, 2026 · PMID 42736457 · candidate dictionary pubmed
SAT1 promotes prostate cancer progression and decreases enzalutamide sensitivity by enhancing spermine catabolism.
Yixin Qu, Shengqiang Zhou, Yuanyuan Li et al. · Hum Cell · Sep 15, 2026 · PMID 42744967 · candidate dictionary pubmed
Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.
Tarek Taha, Ossian Longoria, Johann de Bono · Eur Urol · Sep 15, 2026 · PMID 42744693 · candidate dictionary pubmed
Ten-year outcomes of PET-directed salvage nodal radiotherapy and temporary ADT for N1 and M1a hormone-sensitive prostate cancer.
Cristian J Salazar V, Tyler J Wilhite, Bradley J Stish et al. · Pract Radiat Oncol · Sep 15, 2026 · PMID 42744091 · candidate dictionary pubmed
Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer.
Elio Adib, Emerson Lee, Yu-Hui Chen et al. · Radiother Oncol · Sep 15, 2026 · PMID 42744074 · candidate dictionary pubmed

Advanced stage and biochemical recurrence of grade group 1 prostate cancer after radical prostatectomy.

Matei M Buzoianu, Behfar Ehdaie, Andrew J Vickers · J Urol · Sep 14, 2026 · PMID 42735394 · candidate dictionary pubmed

Adoption of Hypofractionated Radiation Therapy and Quality of Life Outcomes for Localised Prostate Cancer in an Australian Population-Based Cohort.

Therese Min Jung Kang, Diane Laura Lim, Sunwoo Kim et al. · J Med Imaging Radiat Oncol · Sep 14, 2026 · PMID 42734060 · candidate dictionary pubmed

[177Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME).

Piyush Aggarwal, Ashwani Sood, Swayamjeet Satapathy et al. · Prostate · Sep 13, 2026 · PMID 42732593 · candidate dictionary pubmed

Prognostic Value of MRI-Derived Apparent Diffusion Coefficient in Intermediate-Risk Prostate Cancer Treated With Definitive Radiotherapy.

Cem Onal, Gurcan Erbay, Aysenur Elmali et al. · Prostate · Sep 13, 2026 · PMID 42732567 · candidate dictionary pubmed

Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

Jennifer L Marte, Amy Hankin, Monique Williams et al. · BJU Int · Sep 13, 2026 · PMID 42733186 · candidate dictionary pubmed

Patient-clinician symptom agreement before and after radiotherapy for prostate cancer: results from the randomized HYPO-RT-PC study.

Ulrika Rönningås, Lars Beckman, Anna-Karin Wennstig et al. · Radiother Oncol · Sep 13, 2026 · PMID 42732820 · candidate dictionary pubmed

A Spatial Perspective on Extraprostatic Extension in Prostate Cancer: Multiscale Geometric Analysis of Multiparametric MRI.

Haiyue Xiong, Feng Zou, Jun Chen et al. · Acad Radiol · Sep 12, 2026 · PMID 42731898 · candidate dictionary pubmed

Associations between CT-Based Body Composition and Cardiotoxicity and Overall Survival in Patients with Prostate Cancer.

Xun Qiu, Hesong Shen, Chunrong Tu et al. · Acad Radiol · Sep 12, 2026 · PMID 42731897 · candidate dictionary pubmed

PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy.

Sanam Shafaattalab, Alexander Partin, Aaron Winters et al. · J Immunother Cancer · Sep 12, 2026 · PMID 42731875 · candidate dictionary pubmed

Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36 months of androgen deprivation therapy and radiotherapy: a systematic literature review.

Vérane Achard, Almuneda Zapatero, Amar U Kishan et al. · Radiother Oncol · Sep 12, 2026 · PMID 42731757 · candidate dictionary pubmed

Metabolic plasticity in castration-resistant prostate cancer: reprogramming mechanisms and therapeutic opportunities.

Yanzhi Lou, Zhengda Lou, Luo He et al. · Cell Signal · Sep 12, 2026 · PMID 42731739 · candidate dictionary pubmed

Salvage therapy for radiorecurrent prostate cancer: beyond equipoise - a call for biomarker-driven stratification.

Qing-Hua Ke, Shi-Qiong Zhou · Transl Oncol · Sep 12, 2026 · PMID 42731418 · candidate dictionary pubmed

Surgical techniques that improve urinary continence and sexual outcomes in patients undergoing robotic prostatectomy for prostate cancer: a narrative review.

Pushan Prabhakar, Jaya Krishnan, Mohamed Javid Raja Iyub et al. · Curr Opin Urol · Sep 11, 2026 · PMID 42673537 · candidate dictionary pubmed

Spatial statistics infer structured immune signatures in primary prostate cancer.

Ali Amiryousefi, Jeremiah Wala, Jia-Ren Lin et al. · Cancer Immunol Res · Sep 11, 2026 · PMID 42726512 · candidate dictionary pubmed

Nutrient deprivation enhances the cytotoxic effects of a sulfonamide-chalcone hybrid in PC-3 prostate cancer cells.

Gisele Santos de Araújo, Rodrigo Elísio de Sá, Stéphanie Aguiar de Negreiros Matos Silva et al. · Mol Cell Biochem · Sep 11, 2026 · PMID 42726371 · candidate dictionary pubmed

Testosterone Therapy After TRAVERSE: Rethinking Cardiovascular and Prostate Cancer Safety.

Gökhan Çevik, Ateş Kadıoğlu · Balkan Med J · Sep 11, 2026 · PMID 42723557 · candidate dictionary pubmed

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy.

Emilio Francesco Giunta, Irene Marini, Ilaria Grassi et al. · Eur J Nucl Med Mol Imaging · Sep 11, 2026 · PMID 42722919 · candidate dictionary pubmed

Tumor-derived CTHRC1 mediates ITGB3-dependent osteoclast differentiation to promote prostate cancer bone metastasis.

Tao Xie, Tianming Peng, Qu Li et al. · Oncogene · Sep 11, 2026 · PMID 42728346 · candidate dictionary pubmed

Cryoablation for localized prostate cancer: Feasibility in large prostates.

Jamie Michael, Kathryn Fink, Vivian Wan et al. · Urol Oncol · Sep 11, 2026 · PMID 42728122 · candidate dictionary pubmed